Qiagen N.V.
QGEN- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001015820
No open-market purchases or sales by Qiagen N.V. insiders were filed in the last 90 days; 337 institutions reported holding it in 13F filings for Q2 2026, worth $5.68B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 337
- 13F valueReported value at the end of Q2 2026
- $5.68B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding QGEN, Q2 2026
No superinvestor reported holding QGEN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Qiagen N.V. insiders from Form 4, newest first.
No open-market purchases or sales by Qiagen N.V. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Qiagen N.V. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wellington Management Group LLP | 12,406,763 | $484.2M | 0.08% | −1,957,540−13.6% | Reduced |
| Price T Rowe Associates Inc | 11,354,379 | $444.0M | 0.04% | +2,925,045+34.7% | Added |
| Principal Financial Group Inc | 6,648,681 | $260.0M | 0.13% | +6,643,158+120,281.7% | Added |
| Vanguard Capital Management LLC | 6,209,904 | $240.2M | 0.01% | +103,629+1.7% | Added |
| BlackRock, Inc. | 5,905,678 | $230.9M | 0.00% | +655,217+12.5% | Added |
| Morgan Stanley | 5,042,391 | $197.2M | 0.01% | +851,478+20.3% | Added |
| Earnest Partners LLC | 4,573,455 | $178.8M | 0.64% | +704,966+18.2% | Added |
| Goldman Sachs Group Inc | 4,443,674 | $173.7M | 0.02% | +3,052,347+219.4% | Added |
| Norges Bank | 4,325,135 | $168.0M | 0.02% | +4,325,135 | New |
| Millennium Management LLC | 3,845,605 | $150.4M | 0.10% | +3,247,768+543.3% | Added |